Skip to main contentSkip to navigationSkip to search

The share

Latest

SEK

(%)

Volume, thousands
[{"d":"2022-04-04","n":"2021 and 2020 Lipid Science Prize awarded to inventors of m-RNA and lipid nanoparticle technologies","u":"/media/press-releases/2022/2021-and-2020-lipid-science-prize-awarded-to-inventors-of-m-rna-and-lipid-nanoparticle-technologies/"},{"d":"2022-04-06","n":"Notice of annual general meeting 2022 in Camurus AB (publ)","u":"/media/press-releases/2022/notice-of-annual-general-meeting-2022-in-camurus-ab-publ/"},{"d":"2022-04-06","n":"Camurus Annual Report for 2021","u":"/media/press-releases/2022/camurus-annual-report-for-2021/"},{"d":"2022-05-12","n":"Resolutions at the annual general meeting 2022 in Camurus","u":"/media/press-releases/2022/resolutions-at-the-annual-general-meeting-2022-in-camurus/"},{"d":"2022-02-16","n":"Camurus’ Full Year Report 2021","u":"/media/press-releases/2022/camurus-full-year-report-2021/"},{"d":"2022-05-12","n":"Camurus' Interim Report January-March 2022","u":"/media/press-releases/2022/camurus-interim-report-january-march-2022/"},{"d":"2022-01-13","n":"Camurus announces dosing initiated in Phase 3 trial of weekly setmelanotide in patients with genetic obesity disorder","u":"/media/press-releases/2022/camurus-announces-dosing-initiated-in-phase-3-trial-of-weekly-setmelanotide-in-patients-with-genetic-obesity-disorder/"},{"d":"2021-12-30","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2021/change-in-number-of-shares-and-votes-in-camurus/"},{"d":"2021-12-15","n":"Braeburn receives new Complete Response Letter for Brixadi in the US","u":"/media/press-releases/2021/braeburn-receives-new-complete-response-letter-for-brixadi-in-the-us/"},{"d":"2021-11-30","n":"The European Medicines Agency accepts application to extend the Buvidal indication to include treatment of chronic pain","u":"/media/press-releases/2021/the-european-medicines-agency-accepts-application-to-extend-the-buvidal-indication-to-include-treatment-of-chronic-pain/"},{"d":"2021-11-11","n":"Camurus announces dosing initiated in Phase 3 study of CAM2029 in patients with neuroendocrine tumors","u":"/media/press-releases/2021/camurus-announces-dosing-initiated-in-phase-3-study-of-cam2029-in-patients-with-neuroendocrine-tumors/"},{"d":"2021-11-04","n":"Camurus’ Interim Report Third Quarter 2021","u":"/media/press-releases/2021/camurus-interim-report-third-quarter-2021/"},{"d":"2021-10-27","n":"Camurus’ Nomination Committee appointed for the Annual General Meeting 2022","u":"/media/press-releases/2021/camurus-nomination-committee-appointed-for-the-annual-general-meeting-2022/"},{"d":"2021-10-13","n":"Camurus appoints Jon U. Garay Alonso as Chief Financial Officer","u":"/media/press-releases/2021/camurus-appoints-jon-u-garay-alonso-as-chief-financial-officer/"},{"d":"2021-09-30","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2021/change-in-number-of-shares-and-votes-in-camurus-2021-09-30/"},{"d":"2021-09-16","n":"FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver disease","u":"/media/press-releases/2021/fda-grants-orphan-drug-designation-in-the-us-for-cam2029-for-the-treatment-of-polycystic-liver-disease/"},{"d":"2021-09-15","n":"Camurus’ Chief Financial Officer (CFO) will leave the company","u":"/media/press-releases/2021/camurus-chief-financial-officer-cfo-will-leave-the-company/"},{"d":"2021-08-31","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2021/change-in-number-of-shares-and-votes-in-camurus-2021-08-31/"},{"d":"2021-07-15","n":"Camurus’ Interim Report Second Quarter 2021","u":"/media/press-releases/2021/camurus-interim-report-second-quarter-2021/"},{"d":"2021-06-30","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2021/change-in-number-of-shares-and-votes-in-camurus-2021-06-30/"},{"d":"2021-06-26","n":"Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US","u":"/media/press-releases/2021/camurus-announces-pdufa-date-for-brixadi-for-the-treatment-of-opioid-use-disorder-in-the-us/"},{"d":"2021-06-15","n":"Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US","u":"/media/press-releases/2021/camurus-announces-braeburn-resubmits-new-drug-application-for-brixadi-in-the-us/"},{"d":"2021-05-31","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2021/change-in-number-of-shares-and-votes-in-camurus-2021-05-31/"},{"d":"2021-05-21","n":"Exercise of Camurus’ subscription warrant program 2018/2021","u":"/media/press-releases/2021/exercise-of-camurus-subscription-warrant-program-20182021/"},{"d":"2021-05-19","n":"Camurus receives Carnegie Sustainability Award 2021","u":"/media/press-releases/2021/camurus-receives-carnegie-sustainability-award-2021/"},{"d":"2021-05-10","n":"Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence","u":"/media/press-releases/2021/camurus-announces-publication-showing-superior-patient-treatment-satisfaction-with-buvidal-weekly-and-monthly-depot-injections-in-opioid-dependence/"},{"d":"2021-05-06","n":"Resolutions at the annual general meeting 2021 in Camurus","u":"/media/press-releases/2021/resolutions-at-the-annual-general-meeting-2021-in-camurus/"},{"d":"2021-05-06","n":"Camurus’ Interim Report January-March 2021","u":"/media/press-releases/2021/camurus-interim-report-january-march-2021/"},{"d":"2021-05-03","n":"The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence","u":"/media/press-releases/2021/the-australian-tga-approves-key-label-updates-to-buvidal-for-treatment-of-opioid-dependence/"},{"d":"2021-04-14","n":"Camurus Annual Report for 2020","u":"/media/press-releases/2021/camurus-annual-report-for-2020/"},{"d":"2021-03-30","n":"Notice of annual general meeting 2021 in Camurus AB (publ)","u":"/media/press-releases/2021/notice-of-annual-general-meeting-2021-in-camurus-ab-publ/"},{"d":"2021-03-26","n":"Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence","u":"/media/press-releases/2021/camurus-receives-positive-chmp-opinion-for-buvidal-160mg-monthly-dose-for-the-treatment-of-opioid-dependence/"},{"d":"2021-02-11","n":"Camurus’ Full Year Report 2020","u":"/media/press-releases/2021/camurus-full-year-report-2020/"},{"d":"2021-01-29","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2021/change-in-number-of-shares-and-votes-in-camurus-2021-01-29/"},{"d":"2021-01-04","n":"Camurus appoints Andrew McLean as Vice President Corporate Development and Senior Counsel","u":"/media/press-releases/2021/camurus-appoints-andrew-mclean-as-vice-president-corporate-development-and-senior-counsel/"},{"d":"2020-12-30","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2020/change-in-number-of-shares-and-votes-in-camurus/"},{"d":"2020-12-18","n":"Swissmedic approves Buvidal for the treatment of opioid dependence","u":"/media/press-releases/2020/swissmedic-approves-buvidal-for-the-treatment-of-opioid-dependence/"},{"d":"2020-12-18","n":"Exercise of Camurus’ subscription warrant program 2017/2020","u":"/media/press-releases/2020/exercise-of-camurus-subscription-warrant-program-20172020/"},{"d":"2020-12-10","n":"Camurus announces outcome of the arbitration process with Braeburn","u":"/media/press-releases/2020/camurus-announces-outcome-of-the-arbitration-process-with-braeburn/"},{"d":"2020-12-02","n":"Camurus announces that Braeburn receives Complete Response Letter for Brixadi for opioid use disorder in the US","u":"/media/press-releases/2020/camurus-announces-that-braeburn-receives-complete-response-letter-for-brixadi-for-opioid-use-disorder-in-the-us/"},{"d":"2020-11-30","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2020/change-in-number-of-shares-and-votes-in-camurus-2020-11-30/"},{"d":"2020-11-05","n":"Camurus’ Interim Report Third Quarter 2020","u":"/media/press-releases/2020/camurus-interim-report-third-quarter-2020/"},{"d":"2020-10-23","n":"Camurus’ Nomination Committee appointed for the Annual General Meeting 2021","u":"/media/press-releases/2020/camurus-nomination-committee-appointed-for-the-annual-general-meeting-2021/"},{"d":"2020-07-31","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2020/change-in-number-of-shares-and-votes-in-camurus-2020-07-31/"},{"d":"2020-07-16","n":"Camurus’ Interim Report Second Quarter 2020","u":"/media/press-releases/2020/camurus-interim-report-second-quarter-2020/"},{"d":"2020-07-02","n":"Camurus has completed a directed share issue of 2 million shares, raising proceeds of SEK 300 million","u":"/media/press-releases/2020/camurus-has-completed-a-directed-share-issue-of-2-million-shares-raising-proceeds-of-sek-300-million/"},{"d":"2020-07-01","n":"Camurus intends to carry out a directed share issue of approximately SEK 300 million","u":"/media/press-releases/2020/camurus-intends-to-carry-out-a-directed-share-issue-of-approximately-sek-300-million/"},{"d":"2020-06-24","n":"Positive results from Phase 2 study of once-weekly FluidCrystal® formulation of setmelanotide in healthy volunteers with obesity","u":"/media/press-releases/2020/positive-results-from-phase-2-study-of-once-weekly-fluidcrystal-formulation-of-setmelanotide-in-healthy-volunteers-with-obesity/"},{"d":"2020-06-23","n":"Camurus raises full year 2020 revenue guidance","u":"/media/press-releases/2020/camurus-raises-full-year-2020-revenue-guidance/"},{"d":"2020-06-15","n":"Braeburn and Camurus enter arbitration proceedings in England","u":"/media/press-releases/2020/braeburn-and-camurus-enter-arbitration-proceedings-in-england/"},{"d":"2020-06-01","n":"Camurus announces submission of request for final approval of Brixadi™ for the treatment of opioid use disorder in the US","u":"/media/press-releases/2020/camurus-announces-submission-of-request-for-final-approval-of-brixadi-for-the-treatment-of-opioid-use-disorder-in-the-us/"},{"d":"2020-05-14","n":"Camurus’ Buvidal® reimbursed in Sweden for the treatment of opioid dependence","u":"/media/press-releases/2020/camurus-buvidal-reimbursed-in-sweden-for-the-treatment-of-opioid-dependence/"},{"d":"2020-05-07","n":"Resolutions at the annual general meeting 2020 in Camurus","u":"/media/press-releases/2020/resolutions-at-the-annual-general-meeting-2020-in-camurus/"},{"d":"2020-05-07","n":"Camurus’ Interim Report January-March 2020","u":"/media/press-releases/2020/camurus-interim-report-january-march-2020/"},{"d":"2020-04-08","n":"Camurus Annual Report for 2019","u":"/media/press-releases/2020/camurus-annual-report-for-2019/"},{"d":"2020-04-06","n":"Notice of annual general meeting 2020 in Camurus AB (publ)","u":"/media/press-releases/2020/notice-of-annual-general-meeting-2020-in-camurus-ab-publ/"},{"d":"2020-04-02","n":"Camurus announces strong first quarter demand for Buvidal®","u":"/media/press-releases/2020/camurus-announces-strong-first-quarter-demand-for-buvidal/"},{"d":"2020-02-12","n":"Camurus Full year report 2019","u":"/media/press-releases/2020/camurus-full-year-report-2019/"},{"d":"2019-12-30","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2019/change-in-number-of-shares-and-votes-in-camurus/"},{"d":"2019-12-06","n":"Camurus has completed a directed share issue of approximately 3.7 million shares, raising proceeds of approximately 300 MSEK","u":"/media/press-releases/2019/camurus-has-completed-a-directed-share-issue-of-approximately-37-million-shares-raising-proceeds-of-approximately-300-msek/"},{"d":"2019-12-05","n":"Camurus intends to launch a directed share issue of up to 300 MSEK","u":"/media/press-releases/2019/camurus-intends-to-launch-a-directed-share-issue-of-up-to-300-msek/"},{"d":"2019-11-26","n":"Camurus announces new study results showing superior patient reported outcomes with Buvidal® versus standard of care in treatment of opioid dependence","u":"/media/press-releases/2019/camurus-announces-new-study-results-showing-superior-patient-reported-outcomes-with-buvidal-versus-standard-of-care-in-treatment-of-opioid-dependence/"},{"d":"2019-11-08","n":"Camurus Interim Report January-September 2019","u":"/media/press-releases/2019/camurus-interim-report-january-september-2019/"},{"d":"2019-11-08","n":"Camurus announces that FDA grants Braeburn’s Citizen Petition, eliminating the risk of further blocking of Brixadi™ from the US market","u":"/media/press-releases/2019/camurus-announces-that-fda-grants-braeburns-citizen-petition-eliminating-the-risk-of-further-blocking-of-brixadi-from-the-us-market/"},{"d":"2019-10-21","n":"Camurus to present at Jefferies 2019 London Healthcare Conference","u":"/media/press-releases/2019/camurus-to-present-at-jefferies-2019-london-healthcare-conference/"},{"d":"2019-10-15","n":"Camurus’ Nomination Committee appointed for the Annual General Meeting 2020","u":"/media/press-releases/2019/camurus-nomination-committee-appointed-for-the-annual-general-meeting-2020/"},{"d":"2019-08-26","n":"Australian Minister for Health announced PBS listing of Buvidal® Weekly and Monthly for treatment of opioid dependence","u":"/media/press-releases/2019/australian-minister-for-health-announced-pbs-listing-of-buvidal-weekly-and-monthly-for-treatment-of-opioid-dependence/"},{"d":"2019-07-23","n":"Camurus announces positive outcome of US court proceeding about final approval of Brixadi™","u":"/media/press-releases/2019/camurus-announces-positive-outcome-of-us-court-proceeding-about-final-approval-of-brixadi/"},{"d":"2019-07-18","n":"Interim Report January-June 2019","u":"/media/press-releases/2019/interim-report-january-june-2019/"},{"d":"2019-07-16","n":"Ra Pharmaceuticals and Camurus Announce Exclusive License Agreement for FluidCrystal® Extended Release Formulation of Zilucoplan","u":"/media/press-releases/2019/ra-pharmaceuticals-and-camurus-announce-exclusive-license-agreement-for-fluidcrystal-extended-release-formulation-of-zilucoplan/"},{"d":"2019-06-20","n":"Camurus receives IND acceptance from the FDA to enter Phase 3 with CAM2029 for treatment of acromegaly","u":"/media/press-releases/2019/camurus-receives-ind-acceptance-from-the-fda-to-enter-phase-3-with-cam2029-for-treatment-of-acromegaly/"},{"d":"2019-06-04","n":"Camurus announces publication of Phase 3 study results showing long-term safety, efficacy and high rates of patient satisfaction with Buvidal®","u":"/media/press-releases/2019/camurus-announces-publication-of-phase-3-study-results-showing-long-term-safety-efficacy-and-high-rates-of-patient-satisfaction-with-buvidal/"},{"d":"2019-05-09","n":"Resolutions at the annual general meeting 2019 in Camurus","u":"/media/press-releases/2019/resolutions-at-the-annual-general-meeting-2019-in-camurus/"},{"d":"2019-05-09","n":"Camurus Interim Report January-March 2019","u":"/media/press-releases/2019/camurus-interim-report-january-march-2019/"},{"d":"2019-05-07","n":"Camurus to present Interim report January-March 2019 on 9 May","u":"/media/press-releases/2019/camurus-to-present-interim-report-january-march-2019-on-9-may/"},{"d":"2019-04-15","n":"Camurus Annual Report for 2018","u":"/media/press-releases/2019/camurus-annual-report-for-2018/"},{"d":"2019-04-09","n":"Braeburn initiates court proceedings to overturn exclusivity and seeks immediate market approval of Brixadi™ in the US","u":"/media/press-releases/2019/braeburn-initiates-court-proceedings-to-overturn-exclusivity-and-seeks-immediate-market-approval-of-brixadi-in-the-us/"},{"d":"2019-04-06","n":"Positive treatment results for Buvidal® in fentanyl users presented at the ASAM 50th Annual Conference","u":"/media/press-releases/2019/positive-treatment-results-for-buvidal-in-fentanyl-users-presented-at-the-asam-50th-annual-conference/"},{"d":"2019-04-05","n":"Notice of annual general meeting 2019 in Camurus AB (publ)","u":"/media/press-releases/2019/notice-of-annual-general-meeting-2019-in-camurus-ab-publ/"},{"d":"2019-03-29","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2019/change-in-number-of-shares-and-votes-in-camurus-2019-03-29/"},{"d":"2019-03-27","n":"Camurus’ rights issue oversubscribed","u":"/media/press-releases/2019/camurus-rights-issue-oversubscribed/"},{"d":"2019-03-26","n":"New date for publication of Camurus’ Annual Report 2018","u":"/media/press-releases/2019/new-date-for-publication-of-camurus-annual-report-2018/"},{"d":"2019-03-08","n":"Camurus publishes prospectus relating to the rights issue","u":"/media/press-releases/2019/camurus-publishes-prospectus-relating-to-the-rights-issue/"},{"d":"2019-03-05","n":"Resolutions at the Extraordinary General Meeting in Camurus","u":"/media/press-releases/2019/resolutions-at-the-extraordinary-general-meeting-in-camurus/"},{"d":"2019-02-28","n":"Camurus announces the terms of its rights issue","u":"/media/press-releases/2019/camurus-announces-the-terms-of-its-rights-issue/"},{"d":"2019-02-14","n":"Camurus to present at the Cowen and Company Annual Healthcare Conference 2019","u":"/media/press-releases/2019/camurus-to-present-at-the-cowen-and-company-annual-healthcare-conference-2019/"},{"d":"2019-02-06","n":"Full year report 2018","u":"/media/press-releases/2019/full-year-report-2018/"},{"d":"2019-02-06","n":"Notice of extraordinary general meeting in Camurus AB (publ)","u":"/media/press-releases/2019/notice-of-extraordinary-general-meeting-in-camurus-ab-publ/"},{"d":"2019-02-06","n":"Camurus to progress commercialization of Buvidal and advance pipeline programs through a fully underwritten rights issue of SEK 400 million","u":"/media/press-releases/2019/camurus-to-progress-commercialization-of-buvidal-and-advance-pipeline-programs-through-a-fully-underwritten-rights-issue-of-sek-400-million/"},{"d":"2019-02-01","n":"Camurus to present full year 2018 results on 6 February","u":"/media/press-releases/2019/camurus-to-present-full-year-2018-results-on-6-february/"},{"d":"2019-01-18","n":"Camurus to present at SEB Biotech Seminar in Stockholm","u":"/media/press-releases/2019/camurus-to-present-at-seb-biotech-seminar-in-stockholm/"},{"d":"2019-01-11","n":"Buvidal® launched as the first long-acting opioid dependence treatment in the EU","u":"/media/press-releases/2019/buvidal-launched-as-the-first-long-acting-opioid-dependence-treatment-in-the-eu/"},{"d":"2018-12-23","n":"US FDA issues a tentative approval of Brixadi™ (buprenorphine) extended-release injection for treatment of opioid use disorder","u":"/media/press-releases/2018/us-fda-issues-a-tentative-approval-of-brixadi-buprenorphine-extended-release-injection-for-treatment-of-opioid-use-disorder/"},{"d":"2018-12-11","n":"Camurus Capital Markets and R&D Day 11 December 2018","u":"/media/press-releases/2018/camurus-capital-markets-and-rd-day-11-december-2018/"},{"d":"2018-11-28","n":"Buvidal® Weekly and Buvidal® Monthly (CAM2038) approved in Australia as the first long-acting treatment of opioid dependence","u":"/media/press-releases/2018/buvidal-weekly-and-buvidal-monthly-cam2038-approved-in-australia-as-the-first-long-acting-treatment-of-opioid-dependence/"},{"d":"2018-11-28","n":"Program for Camurus Capital Markets and R&D Day 11 December 2018","u":"/media/press-releases/2018/program-for-camurus-capital-markets-and-rd-day-11-december-2018/"},{"d":"2018-11-22","n":"Camurus receives EU approval for weekly and monthly Buvidal® (CAM2038) for opioid dependence","u":"/media/press-releases/2018/camurus-receives-eu-approval-for-weekly-and-monthly-buvidal-cam2038-for-opioid-dependence/"},{"d":"2018-10-25","n":"Interim Report January-September 2018","u":"/media/press-releases/2018/interim-report-january-september-2018/"},{"d":"2018-10-16","n":"Camurus’ Nomination Committee appointed for the Annual General Meeting 2019","u":"/media/press-releases/2018/camurus-nomination-committee-appointed-for-the-annual-general-meeting-2019/"},{"d":"2018-10-10","n":"Camurus to present at Jefferies 2018 London Healthcare Conference","u":"/media/press-releases/2018/camurus-to-present-at-jefferies-2018-london-healthcare-conference/"},{"d":"2018-10-09","n":"Save the date: Camurus Capital Markets and R&D Day 11 December 2018","u":"/media/press-releases/2018/save-the-date-camurus-capital-markets-and-rd-day-11-december-2018/"},{"d":"2018-09-21","n":"CHMP recommends approval of Buvidal® (CAM2038) for the treatment of opioid dependence","u":"/media/press-releases/2018/chmp-recommends-approval-of-buvidal-cam2038-for-the-treatment-of-opioid-dependence/"},{"d":"2018-09-18","n":"Camurus announces positive topline Phase 3 results for CAM2038 in opioid experienced patients with chronic low-back pain","u":"/media/press-releases/2018/camurus-announces-positive-topline-phase-3-results-for-cam2038-in-opioid-experienced-patients-with-chronic-low-back-pain/"},{"d":"2018-07-17","n":"Interim Report January-June 2018","u":"/media/press-releases/2018/interim-report-january-june-2018/"},{"d":"2018-07-16","n":"Camurus announces PDUFA date for CAM2038 for the treatment of opioid use disorder","u":"/media/press-releases/2018/camurus-announces-pdufa-date-for-cam2038-for-the-treatment-of-opioid-use-disorder/"},{"d":"2018-06-29","n":"Change in the number of shares and votes in Camurus AB","u":"/media/press-releases/2018/change-in-the-number-of-shares-and-votes-in-camurus-ab/"},{"d":"2018-06-29","n":"Camurus has completed a directed share issue of 1.1 million shares, raising proceeds of approximately SEK 102 million","u":"/media/press-releases/2018/camurus-has-completed-a-directed-share-issue-of-11-million-shares-raising-proceeds-of-approximately-sek-102-million/"},{"d":"2018-06-28","n":"Camurus updates its investor relations website","u":"/media/press-releases/2018/camurus-updates-its-investor-relations-website/"},{"d":"2018-06-28","n":"Camurus intends to launch a directed share issue of approx. MSEK 100","u":"/media/press-releases/2018/camurus-intends-to-launch-a-directed-share-issue-of-approx-msek-100/"},{"d":"2018-06-12","n":"Camurus and Medison enter into commercialization agreement for CAM2038 in Israel","u":"/media/press-releases/2018/camurus-and-medison-enter-into-commercialization-agreement-for-cam2038-in-israel/"},{"d":"2018-05-31","n":"Camurus announces positive topline results from Phase 1 study of long-acting treprostinil for the treatment of pulmonary arterial hypertension","u":"/media/press-releases/2018/camurus-announces-positive-topline-results-from-phase-1-study-of-long-acting-treprostinil-for-the-treatment-of-pulmonary-arterial-hypertension/"},{"d":"2018-05-28","n":"Camurus announces NDA resubmission of weekly and monthly buprenorphine depots to FDA","u":"/media/press-releases/2018/camurus-announces-nda-resubmission-of-weekly-and-monthly-buprenorphine-depots-to-fda/"},{"d":"2018-05-25","n":"Camurus to present at the Jefferies 2018 Global Healthcare Conference","u":"/media/press-releases/2018/camurus-to-present-at-the-jefferies-2018-global-healthcare-conference/"},{"d":"2018-05-14","n":"JAMA Internal Medicine publishes positive Phase 3 pivotal study results for Camurus’ long-acting buprenorphine depots for opioid use disorder","u":"/media/press-releases/2018/jama-internal-medicine-publishes-positive-phase-3-pivotal-study-results-for-camurus-long-acting-buprenorphine-depots-for-opioid-use-disorder/"},{"d":"2018-05-03","n":"Resolutions at the annual general meeting 2018 in Camurus","u":"/media/press-releases/2018/resolutions-at-the-annual-general-meeting-2018-in-camurus/"},{"d":"2018-05-03","n":"Interim Report January-March 2018","u":"/media/press-releases/2018/interim-report-january-march-2018/"},{"d":"2018-05-03","n":"Camurus regains worldwide development and commercialization rights to CAM2029 and related product candidates","u":"/media/press-releases/2018/camurus-regains-worldwide-development-and-commercialization-rights-to-cam2029-and-related-product-candidates/"},{"d":"2018-03-23","n":"Notice of annual general meeting 2018 in Camurus AB (publ)","u":"/media/press-releases/2018/notice-of-annual-general-meeting-2018-in-camurus-ab-publ/"},{"d":"2018-03-22","n":"Camurus Annual Report for 2017","u":"/media/press-releases/2018/camurus-annual-report-for-2017/"},{"d":"2018-03-08","n":"Camurus to present at the Cowen and Company Annual Healthcare Conference 2018","u":"/media/press-releases/2018/camurus-to-present-at-the-cowen-and-company-annual-healthcare-conference-2018/"},{"d":"2018-02-15","n":"Full year report 2017","u":"/media/press-releases/2018/full-year-report-2017/"},{"d":"2018-01-21","n":"FDA issues complete response letter for CAM2038 for opioid use disorder","u":"/media/press-releases/2018/fda-issues-complete-response-letter-for-cam2038-for-opioid-use-disorder/"},{"d":"2017-12-21","n":"First cohort dosed in Phase 1 clinical study of sustained release treprostinil injection for treatment of PAH","u":"/media/press-releases/2017/first-cohort-dosed-in-phase-1-clinical-study-of-sustained-release-treprostinil-injection-for-treatment-of-pah/"},{"d":"2017-11-07","n":"Camurus to present at Jefferies 2017 London Healthcare Conference","u":"/media/press-releases/2017/camurus-to-present-at-jefferies-2017-london-healthcare-conference/"},{"d":"2017-11-01","n":"Camurus announces that FDA advisory committee recommends approval of CAM2038 for treatment of opioid use disorder","u":"/media/press-releases/2017/camurus-announces-that-fda-advisory-committee-recommends-approval-of-cam2038-for-treatment-of-opioid-use-disorder/"},{"d":"2017-10-30","n":"Camurus announces that FDA has posted briefing material for CAM2038 Advisory Committee meeting","u":"/media/press-releases/2017/camurus-announces-that-fda-has-posted-briefing-material-for-cam2038-advisory-committee-meeting/"},{"d":"2017-10-26","n":"Interim Report January-September 2017","u":"/media/press-releases/2017/interim-report-january-september-2017/"},{"d":"2017-10-20","n":"Nomination Committee appointed in respect of AGM 2018 in Camurus","u":"/media/press-releases/2017/nomination-committee-appointed-in-respect-of-agm-2018-in-camurus/"},{"d":"2017-09-29","n":"Camurus announces European Medicines Agency validation of CAM2038 Marketing Authorization Application for treatment of opioid dependence","u":"/media/press-releases/2017/camurus-announces-european-medicines-agency-validation-of-cam2038-marketing-authorization-application-for-treatment-of-opioid-dependence/"},{"d":"2017-09-18","n":"Camurus Announces that FDA Grants Priority Review of NDA for Weekly and Monthly CAM2038 Buprenorphine Depots for Treatment of Opioid Use Disorder","u":"/media/press-releases/2017/camurus-announces-that-fda-grants-priority-review-of-nda-for-weekly-and-monthly-cam2038-buprenorphine-depots-for-treatment-of-opioid-use-disorder/"},{"d":"2017-07-20","n":"Camurus and Braeburn Announce Submission of NDA for Long-Acting Buprenorphine (CAM2038) for Opioid Use Disorder","u":"/media/press-releases/2017/camurus-and-braeburn-announce-submission-of-nda-for-long-acting-buprenorphine-cam2038-for-opioid-use-disorder/"},{"d":"2017-07-13","n":"Interim report January-June 2017","u":"/media/press-releases/2017/interim-report-january-june-2017/"},{"d":"2017-07-12","n":"Camurus and Braeburn Pharmaceuticals Announce Topline Phase 2 Results for Long-acting Buprenorphine in Opioid Dependent Patients with Chronic Pain","u":"/media/press-releases/2017/camurus-and-braeburn-pharmaceuticals-announce-topline-phase-2-results-for-long-acting-buprenorphine-in-opioid-dependent-patients-with-chronic-pain/"},{"d":"2017-06-27","n":"Rhythm and Camurus Announce Positive Initial Data for Extended-Release Delivery of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity","u":"/media/press-releases/2017/rhythm-and-camurus-announce-positive-initial-data-for-extended-release-delivery-of-setmelanotide-for-treatment-of-rare-genetic-disorders-of-obesity/"},{"d":"2017-06-22","n":"Long-acting Buprenorphine Blocks Opioid Effects and Suppresses Withdrawal Symptoms in Adults with Opioid Use Disorder","u":"/media/press-releases/2017/long-acting-buprenorphine-blocks-opioid-effects-and-suppresses-withdrawal-symptoms-in-adults-with-opioid-use-disorder/"},{"d":"2017-06-15","n":"Camurus and Braeburn Pharmaceuticals Announce Presentations of Pivotal Clinical Study Data of Long-acting Buprenorphine","u":"/media/press-releases/2017/camurus-and-braeburn-pharmaceuticals-announce-presentations-of-pivotal-clinical-study-data-of-long-acting-buprenorphine/"},{"d":"2017-05-03","n":"Resolutions at the annual general meeting 2017 in Camurus","u":"/media/press-releases/2017/resolutions-at-the-annual-general-meeting-2017-in-camurus/"},{"d":"2017-05-03","n":"Interim Report January-March 2017","u":"/media/press-releases/2017/interim-report-january-march-2017/"},{"d":"2017-05-02","n":"Camurus and Braeburn Pharmaceuticals Announce Positive Top-line Results from Long-term Phase 3 Safety Study of CAM2038","u":"/media/press-releases/2017/camurus-and-braeburn-pharmaceuticals-announce-positive-top-line-results-from-long-term-phase-3-safety-study-of-cam2038/"},{"d":"2017-03-31","n":"Camurus appoints VP Corporate Development & General Counsel","u":"/media/press-releases/2017/camurus-appoints-vp-corporate-development--general-counsel/"},{"d":"2017-03-30","n":"Camurus Annual Report for 2016 released","u":"/media/press-releases/2017/camurus-annual-report-for-2016-released/"},{"d":"2017-03-30","n":"Notice of annual general meeting 2017 in Camurus AB (publ)","u":"/media/press-releases/2017/notice-of-annual-general-meeting-2017-in-camurus-ab-publ/"},{"d":"2017-03-09","n":"Ethypharm and Camurus sign agreement for distribution of episil® in France","u":"/media/press-releases/2017/ethypharm-and-camurus-sign-agreement-for-distribution-of-episil-in-france/"},{"d":"2017-02-16","n":"Full year report 2016","u":"/media/press-releases/2017/full-year-report-2016/"},{"d":"2017-02-02","n":"Camurus to present at the Cowen and Company Annual Healthcare Conference 2017","u":"/media/press-releases/2017/camurus-to-present-at-the-cowen-and-company-annual-healthcare-conference-2017/"},{"d":"2017-01-09","n":"Camurus to present at the J.P. Morgan Annual Healthcare Conference 2017","u":"/media/press-releases/2017/camurus-to-present-at-the-jp-morgan-annual-healthcare-conference-2017/"},{"d":"2016-12-14","n":"Camurus Capital Markets and R&D Day 2016","u":"/media/press-releases/2016/camurus-capital-markets-and-rd-day-2016/"},{"d":"2016-11-25","n":"Program for Camurus’ Capital Markets and R&D Day 14 December 2016","u":"/media/press-releases/2016/program-for-camurus-capital-markets-and-rd-day-14-december-2016/"},{"d":"2016-11-14","n":"Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Phase 3 Results for Long-acting Buprenorphine for Treatment of Opioid Addiction","u":"/media/press-releases/2016/braeburn-pharmaceuticals-and-camurus-announce-positive-top-line-phase-3-results-for-long-acting-buprenorphine-for-treatment-of-opioid-addiction/"},{"d":"2016-11-11","n":"Camurus to provide an update on the progress of its research and development programs at the Jefferies 2016 Healthcare Conference","u":"/media/press-releases/2016/camurus-to-provide-an-update-on-the-progress-of-its-research-and-development-programs-at-the-jefferies-2016-healthcare-conference/"},{"d":"2016-11-08","n":"Interim report January-September 2016","u":"/media/press-releases/2016/interim-report-january-september-2016/"},{"d":"2016-11-01","n":"Camurus to host a Capital Markets Day 14 December 2016","u":"/media/press-releases/2016/camurus-to-host-a-capital-markets-day-14-december-2016/"},{"d":"2016-10-28","n":"Nomination Committee appointed in respect of AGM 2017 in Camurus","u":"/media/press-releases/2016/nomination-committee-appointed-in-respect-of-agm-2017-in-camurus/"},{"d":"2016-10-24","n":"Braeburn Pharmaceuticals and Camurus Expand Collaboration and License Agreement to include New Combination Product for Pain and Nausea","u":"/media/press-releases/2016/braeburn-pharmaceuticals-and-camurus-expand-collaboration-and-license-agreement-to-include-new-combination-product-for-pain-and-nausea/"},{"d":"2016-10-21","n":"Braeburn Pharmaceuticals and Camurus announce the presentation of new data from clinical studies of long-acting buprenorphine","u":"/media/press-releases/2016/braeburn-pharmaceuticals-and-camurus-announce-the-presentation-of-new-data-from-clinical-studies-of-long-acting-buprenorphine/"},{"d":"2016-09-30","n":"Braeburn Pharmaceuticals and Camurus Enroll First Patients in a Phase 3 Efficacy Trial of CAM2038 for treatment of Chronic Low Back Pain","u":"/media/press-releases/2016/braeburn-pharmaceuticals-and-camurus-enroll-first-patients-in-a-phase-3-efficacy-trial-of-cam2038-for-treatment-of-chronic-low-back-pain/"},{"d":"2016-07-14","n":"Interim report January-June 2016","u":"/media/press-releases/2016/interim-report-january-june-2016/"},{"d":"2016-07-12","n":"Camurus announces completion of Phase 2 study of CAM2029 in patients with acromegaly and neuroendocrine tumors","u":"/media/press-releases/2016/camurus-announces-completion-of-phase-2-study-of-cam2029-in-patients-with-acromegaly-and-neuroendocrine-tumors/"},{"d":"2016-06-21","n":"Camurus announces results from a Phase 2 trial of CAM2032 in patients with prostate cancer","u":"/media/press-releases/2016/camurus-announces-results-from-a-phase-2-trial-of-cam2032-in-patients-with-prostate-cancer/"},{"d":"2016-06-20","n":"Richard Jameson assumes position as Camurus’ Chief Commercial Officer","u":"/media/press-releases/2016/richard-jameson-assumes-position-as-camurus-chief-commercial-officer/"},{"d":"2016-05-17","n":"Camurus Interim Report January-March 2016","u":"/media/press-releases/2016/camurus-interim-report-january-march-2016/"},{"d":"2016-05-11","n":"Braeburn Pharmaceuticals and Camurus announce positive results from Phase 2 opioid challenge study with CAM2038 in subjects with opioid use disorder","u":"/media/press-releases/2016/braeburn-pharmaceuticals-and-camurus-announce-positive-results-from-phase-2-opioid-challenge-study-with-cam2038-in-subjects-with-opioid-use-disorder/"},{"d":"2016-05-03","n":"Resolutions at the Annual General Meeting 2016 in Camurus","u":"/media/press-releases/2016/resolutions-at-the-annual-general-meeting-2016-in-camurus/"},{"d":"2016-04-21","n":"Distribution agreement signed with R-PHARM US for episil®","u":"/media/press-releases/2016/distribution-agreement-signed-with-r-pharm-us-for-episil/"},{"d":"2016-04-05","n":"Braeburn Pharmaceuticals and Camurus announce Enrollment goals reached in two pivotal Phase 3 Trials of CAM2038 for treatment of opioid dependence","u":"/media/press-releases/2016/braeburn-pharmaceuticals-and-camurus-announce-enrollment-goals-reached-in-two-pivotal-phase-3-trials-of-cam2038-for-treatment-of-opioid-dependence/"},{"d":"2016-03-30","n":"Notice of annual general meeting 2016 and proposal for new incentive program in Camurus AB (publ)","u":"/media/press-releases/2016/notice-of-annual-general-meeting-2016-and-proposal-for-new-incentive-program-in-camurus-ab-publ/"},{"d":"2016-03-30","n":"Camurus Annual Report for 2015 released","u":"/media/press-releases/2016/camurus-annual-report-for-2015-released/"},{"d":"2016-02-22","n":"Braeburn and Camurus Announce Initiation of a Phase 2 Study in Opioid Dependent Patients with Moderate to Severe Chronic Pain","u":"/media/press-releases/2016/braeburn-and-camurus-announce-initiation-of-a-phase-2-study-in-opioid-dependent-patients-with-moderate-to-severe-chronic-pain/"},{"d":"2016-02-17","n":"Full year report January-December 2015","u":"/media/press-releases/2016/full-year-report-january-december-2015/"},{"d":"2016-02-04","n":"Nomination Committee appointed in respect of AGM 2016 in Camurus","u":"/media/press-releases/2016/nomination-committee-appointed-in-respect-of-agm-2016-in-camurus/"},{"d":"2016-01-05","n":"Rhythm and Camurus Announce License Agreement for Extended Release FluidCrystal Setmelanotide","u":"/media/press-releases/2016/rhythm-and-camurus-announce-license-agreement-for-extended-release-fluidcrystal-setmelanotide/"},{"d":"2015-12-30","n":"Braeburn Pharmaceuticals and Camurus enroll first patient in a phase 3 efficacy trial of long-acting treatment for opioid dependence","u":"/media/press-releases/2015/braeburn-pharmaceuticals-and-camurus-enroll-first-patient-in-a-phase-3-efficacy-trial-of-long-acting-treatment-for-opioid-dependence/"},{"d":"2015-12-30","n":"Change in the number of shares and votes in Camurus","u":"/media/press-releases/2015/change-in-the-number-of-shares-and-votes-in-camurus/"},{"d":"2015-12-15","n":"Braeburn Pharmaceuticals and Camurus announce start of Phase 3 trial of long-acting buprenorphine treatments for opioid dependence","u":"/media/press-releases/2015/braeburn-pharmaceuticals-and-camurus-announce-start-of-phase-3-trial-of-long-acting-buprenorphine-treatments-for-opioid-dependence/"},{"d":"2015-12-14","n":"Camurus appoints Chief Commercial Officer","u":"/media/press-releases/2015/camurus-appoints-chief-commercial-officer/"},{"d":"2015-12-10","n":"Exercise of the over-allotment option in the initial public offering of Camurus","u":"/media/press-releases/2015/exercise-of-the-over-allotment-option-in-the-initial-public-offering-of-camurus/"},{"d":"2015-12-03","n":"Final price in Camurus’s initial public offering set at SEK 57 per share – trading on Nasdaq Stockholm commences today","u":"/media/press-releases/2015/final-price-in-camuruss-initial-public-offering-set-at-sek-57-per-share--trading-on-nasdaq-stockholm-commences-today/"},{"d":"2015-11-19","n":"Camurus announces initial public offering on Nasdaq Stockholm","u":"/media/press-releases/2015/camurus-announces-initial-public-offering-on-nasdaq-stockholm/"},{"d":"2015-11-18","n":"Camurus announces initial public offering on Nasdaq Stockholm","u":"/media/press-releases/2015/camurus-announces-initial-public-offering-on-nasdaq-stockholm-2015-11-18/"},{"d":"2015-11-04","n":"FDA grants Fast Track designation for development of CAM2038, long-acting buprenorphine injections to treat opioid addiction","u":"/media/press-releases/2015/fda-grants-fast-track-designation-for-development-of-cam2038-long-acting-buprenorphine-injections-to-treat-opioid-addiction/"},{"d":"2015-10-22","n":"Camurus AB Interim Report, January - September 2015","u":"/media/press-releases/2015/camurus-ab-interim-report-january---september-2015/"},{"d":"2015-03-30","n":"Solasia acquires exclusive license and distribution rights from Camurus for episil® oral liquid in Japan and China","u":"/media/press-releases/2015/solasia-acquires-exclusive-license-and-distribution-rights-from-camurus-for-episil-oral-liquid-in-japan-and-china/"},{"d":"2014-11-20","n":"Camurus and Braeburn Pharmaceuticals sign exclusive license for long-acting buprenorphine injectables for the treatment of opioid dependence and pain","u":"/media/press-releases/2014/camurus-and-braeburn-pharmaceuticals-sign-exclusive-license-for-long-acting-buprenorphine-injectables-for-the-treatment-of-opioid-dependence-and-pain/"}]
Download as Excel

Share data

Symbol CAMX
Currency SEK
Market place Market place
Latest price
Ask
Bid
High
Year high
All time high
Low
Year low
All time low
Volume
Number of shares

Shareholders

Shareholders as of 30 April 2022Amount of shares% of capital% of votes
Sandberg Development AB21,875,69239.939.9
Fjärde AP-fonden3,502,4506.46.4
Avanza Pension2,672,0444.94.9
Didner & Gerge Fonder Aktiebolag2,572,9774.74.7
Fredrik Tiberg, CEO1,672,7883.03.0
Svenskt Näringsliv1,150,0002.12.1
Lancelot Avalon Master1,000,0001.81.8
Backahill Utveckling826,4911.51.5
State Street Bank and Trust

690,782

1.31.3
JP Morgan Chase Bank633,1901.11.1
Gladiator628,9441.11.1
Öhman Fonder587,9401.11.1
Afa Försäkring545,6601.01.0
Camurus Lipid Research Foundation495,2500.90.9
Carl-Olof och Jenz Hamrins Stiftelse425,0000.80.8
Other shareholders15,549,32628.428.4
In total54,828,584100.0100.0